$196 Million is the total value of NEXTHERA CAPITAL LP's 39 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 110.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | Buy | Pfizer Inc | $26,857,000 | +160.0% | 785,051 | +146.8% | 13.70% | +126.3% |
| SHPG | Sell | Shire PLCsponsored adr | $18,120,000 | -18.2% | 104,000 | -20.0% | 9.25% | -28.8% |
| AZN | New | AstraZeneca PLCcall | $15,259,000 | – | 490,000 | +100.0% | 7.79% | – |
| CELG | Sell | Celgene Corp | $14,932,000 | +5.7% | 120,000 | -1.6% | 7.62% | -7.9% |
| GSK | New | GlaxoSmithKline PLCsponsored adr | $13,344,000 | – | 316,500 | +100.0% | 6.81% | – |
| VRTX | New | Vertex Pharmaceuticals Inccall | $10,935,000 | – | 100,000 | +100.0% | 5.58% | – |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $10,487,000 | -14.3% | 86,500 | -13.5% | 5.35% | -25.4% |
| KITE | Sell | Kite Pharma Inc | $8,241,000 | +22.5% | 105,000 | -30.0% | 4.20% | +6.6% |
| TSRO | New | TESARO Incput | $7,694,000 | – | 50,000 | +100.0% | 3.93% | – |
| New | Neuroderm Ltd | $7,646,000 | – | 288,000 | +100.0% | 3.90% | – | |
| GBT | Buy | Global Blood Therapeutics Inc | $7,536,000 | +769.2% | 204,500 | +240.8% | 3.85% | +657.1% |
| VNDA | New | Vanda Pharmaceuticals Inc | $7,171,000 | – | 512,200 | +100.0% | 3.66% | – |
| ARRY | New | Array BioPharma Inccall | $7,152,000 | – | 800,000 | +100.0% | 3.65% | – |
| NERV | Buy | Minerva Neurosciences Inc | $6,133,000 | +5.9% | 757,200 | +53.6% | 3.13% | -7.8% |
| NLNK | New | NewLink Genetics Corpcall | $4,820,000 | – | 200,000 | +100.0% | 2.46% | – |
| ACRS | New | Aclaris Therapeutics Inc | $3,325,000 | – | 111,500 | +100.0% | 1.70% | – |
| EIGR | Eiger BioPharmaceuticals Inc | $3,018,000 | -1.7% | 263,600 | 0.0% | 1.54% | -14.4% | |
| PRTK | Buy | Paratek Pharmaceuticals Inc | $2,888,000 | +87.5% | 150,000 | +50.0% | 1.47% | +63.2% |
| RXDX | New | Ignyta Inc | $2,881,000 | – | 335,000 | +100.0% | 1.47% | – |
| ABEO | Sell | Abeona Therapeutics Inc | $2,470,000 | -10.4% | 494,064 | -13.1% | 1.26% | -22.1% |
| CARA | Sell | Cara Therapeutics Inc | $2,207,000 | -5.0% | 120,000 | -52.0% | 1.13% | -17.3% |
| AXSM | New | Axsome Therapeutics Inc | $1,560,000 | – | 400,000 | +100.0% | 0.80% | – |
| AXGT | New | Axovant Sciences Ltdcall | $1,494,000 | – | 100,000 | +100.0% | 0.76% | – |
| TIG | New | TiGenix NVsponsored ads | $1,438,000 | – | 92,203 | +100.0% | 0.73% | – |
| MRNS | New | Marinus Pharmaceuticals Inc | $1,416,000 | – | 800,000 | +100.0% | 0.72% | – |
| CARA | New | Cara Therapeutics Inccall | $1,379,000 | – | 75,000 | +100.0% | 0.70% | – |
| CLSD | Clearside Biomedical Inc | $959,000 | -11.2% | 120,763 | 0.0% | 0.49% | -22.7% | |
| ZSAN | New | Zosano Pharma Corp | $950,000 | – | 500,000 | +100.0% | 0.48% | – |
| ADXS | Sell | Advaxis Inc | $791,000 | -44.8% | 96,800 | -51.6% | 0.40% | -51.8% |
| VSTM | Verastem Inc | $696,000 | +85.1% | 336,000 | 0.0% | 0.36% | +61.4% | |
| SRRA | New | Sierra Oncology inc | $612,000 | – | 400,000 | +100.0% | 0.31% | – |
| ALKS | New | Alkermes PLC | $550,000 | – | 9,400 | +100.0% | 0.28% | – |
| OBSV | New | ObsEva SA | $521,000 | – | 50,000 | +100.0% | 0.27% | – |
| VTGN | VistaGen Therapeutics Inc | $271,000 | -47.4% | 138,132 | 0.0% | 0.14% | -54.3% | |
| VBLT | Vascular Biogenics Ltd | $183,000 | +13.0% | 33,332 | 0.0% | 0.09% | -2.1% | |
| STDY | New | SteadyMed Ltd | $31,000 | – | 5,399 | +100.0% | 0.02% | – |
| TCON | Exit | Tracon Pharmaceuticals Inc | $0 | – | -12,714 | -100.0% | -0.04% | – |
| Exit | Amicus Therapeutics Inccall | $0 | – | -100,000 | -100.0% | -0.29% | – | |
| Exit | Intec Pharma Ltd | $0 | – | -138,845 | -100.0% | -0.46% | – | |
| RDHL | Exit | Redhill Biopharma Ltdsponsored ads | $0 | – | -95,000 | -100.0% | -0.58% | – |
| IMDZ | Exit | Immune Design Corp | $0 | – | -198,600 | -100.0% | -0.64% | – |
| Exit | Axovant Sciences Ltdcall | $0 | – | -100,000 | -100.0% | -0.73% | – | |
| SGMO | Exit | Sangamo BioSciences Inc | $0 | – | -503,000 | -100.0% | -0.90% | – |
| CNCE | Exit | Concert Pharmaceuticals Inc | $0 | – | -167,866 | -100.0% | -1.01% | – |
| ZGNX | Exit | Zogenix Inc | $0 | – | -150,000 | -100.0% | -1.07% | – |
| ASND | Exit | Ascendis Pharma A/Ssponsored adr | $0 | – | -100,000 | -100.0% | -1.19% | – |
| Exit | NewLink Genetics Corpcall | $0 | – | -200,000 | -100.0% | -1.20% | – | |
| TRVN | Exit | Trevena Inc | $0 | – | -398,849 | -100.0% | -1.38% | – |
| FGEN | Exit | FibroGen Inc | $0 | – | -116,000 | -100.0% | -1.46% | – |
| ADMS | Exit | Adamas Pharmaceuticals Inc | $0 | – | -151,670 | -100.0% | -1.50% | – |
| INSM | Exit | Insmed Inc | $0 | – | -322,044 | -100.0% | -2.50% | – |
| XLRN | Exit | Acceleron Pharma Inc | $0 | – | -178,000 | -100.0% | -2.66% | – |
| NBIX | Exit | Neurocrine Biosciences Inc | $0 | – | -120,000 | -100.0% | -2.72% | – |
| ALNY | Exit | Alnylam Pharmaceuticals Inc | $0 | – | -165,000 | -100.0% | -3.62% | – |
| Exit | TESARO Incput | $0 | – | -50,000 | -100.0% | -3.94% | – | |
| Exit | AstraZeneca PLCcall | $0 | – | -250,000 | -100.0% | -4.00% | – | |
| HZNP | Exit | Horizon Pharma Plc | $0 | – | -500,000 | -100.0% | -4.74% | – |
| AZN | Exit | AstraZeneca PLCsponsored adr | $0 | – | -300,000 | -100.0% | -4.80% | – |
| NVS | Exit | Novartis AGsponsored adr | $0 | – | -198,000 | -100.0% | -8.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Insmed Inc | 13 | Q2 2019 | 10.0% |
| Global Blood Therapeutics Inc | 11 | Q2 2019 | 6.2% |
| Shire PLC | 9 | Q1 2018 | 13.6% |
| Immunomedics Inc | 9 | Q2 2019 | 7.8% |
| Allergan PLC | 8 | Q2 2019 | 7.6% |
| FibroGen Inc | 8 | Q3 2018 | 3.0% |
| Abeona Therapeutics Inc | 8 | Q3 2018 | 2.1% |
| Pfizer Inc | 7 | Q2 2017 | 19.1% |
| Seattle Genetics Inc | 7 | Q2 2018 | 5.7% |
| Mylan NV | 7 | Q2 2019 | 6.5% |
View NEXTHERA CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CATALYST BIOSCIENCES, INC. | February 14, 2019 | 376,010 | 3.1% |
| CHIASMA, INC | February 14, 2019 | 1,066,439 | 4.4% |
| ONCOSEC MEDICAL IncSold out | February 14, 2019 | 0 | 0.0% |
| Zosano Pharma Corp | April 05, 2018 | 700,000 | 5.9% |
| VistaGen Therapeutics, Inc. | May 24, 2016 | 138,132 | 1.8% |
View NEXTHERA CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G/A | 2019-02-14 |
| SC 13G | 2018-11-26 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| SC 13G | 2018-06-11 |
View NEXTHERA CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.